The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations

M. O. Leach; K. M. Brindle; J. L. Evelhoch; J. R. Griffiths; M. R. Horsman; A. Jackson; G. C. Jayson; I. R. Judson; M. V. Knopp; R. J. Maxwell; D. McIntyre; A. R. Padhani; P. Price; R. Rathbone; G. J. Rustin; P. S. Tofts; G. M. Tozer; W. Vennart; J. C. Waterton; S. R. Williams; P. Workman

doi:10.1038/sj.bjc.6602550

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations

M. O. Leach, K. M. Brindle, J. L. Evelhoch, J. R. Griffiths, M. R. Horsman, A. Jackson, G. C. Jayson, I. R. Judson, M. V. Knopp, R. J. Maxwell, D. McIntyre, A. R. Padhani, P. Price, R. Rathbone, G. J. Rustin, P. S. Tofts, G. M. Tozer, W. Vennart, J. C. Waterton, S. R. WilliamsP. Workman

Cancer Research UK Manchester Institute

Research output: Contribution to journal › Article › peer-review

Abstract

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used. © 2005 Cancer Research UK.

Original language	English
Pages (from-to)	1599-1610
Number of pages	11
Journal	British Journal of Cancer
Volume	92
Issue number	9
DOIs	https://doi.org/10.1038/sj.bjc.6602550
Publication status	Published - 9 May 2005

Keywords

Antiangiogenic
Antivascular
Biomarker
Cancer therapy
Magnetic resonance
Therapeutic trials

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6602550

Cite this

Leach, M. O., Brindle, K. M., Evelhoch, J. L., Griffiths, J. R., Horsman, M. R., Jackson, A., Jayson, G. C., Judson, I. R., Knopp, M. V., Maxwell, R. J., McIntyre, D., Padhani, A. R., Price, P., Rathbone, R., Rustin, G. J., Tofts, P. S., Tozer, G. M., Vennart, W., Waterton, J. C., ... Workman, P. (2005). The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. British Journal of Cancer, 92(9), 1599-1610. https://doi.org/10.1038/sj.bjc.6602550

@article{6845b626fa4d4e5ab444ee690eef0b62,

title = "The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations",

abstract = "Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used. {\textcopyright} 2005 Cancer Research UK.",

keywords = "Antiangiogenic, Antivascular, Biomarker, Cancer therapy, Magnetic resonance, Therapeutic trials",

author = "Leach, {M. O.} and Brindle, {K. M.} and Evelhoch, {J. L.} and Griffiths, {J. R.} and Horsman, {M. R.} and A. Jackson and Jayson, {G. C.} and Judson, {I. R.} and Knopp, {M. V.} and Maxwell, {R. J.} and D. McIntyre and Padhani, {A. R.} and P. Price and R. Rathbone and Rustin, {G. J.} and Tofts, {P. S.} and Tozer, {G. M.} and W. Vennart and Waterton, {J. C.} and Williams, {S. R.} and P. Workman",

year = "2005",

month = may,

day = "9",

doi = "10.1038/sj.bjc.6602550",

language = "English",

volume = "92",

pages = "1599--1610",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "9",

}

Leach, MO, Brindle, KM, Evelhoch, JL, Griffiths, JR, Horsman, MR, Jackson, A , Jayson, GC, Judson, IR, Knopp, MV, Maxwell, RJ, McIntyre, D, Padhani, AR, Price, P, Rathbone, R, Rustin, GJ, Tofts, PS, Tozer, GM, Vennart, W, Waterton, JC, Williams, SR & Workman, P 2005, 'The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations', British Journal of Cancer, vol. 92, no. 9, pp. 1599-1610. https://doi.org/10.1038/sj.bjc.6602550

TY - JOUR

T1 - The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations

AU - Leach, M. O.

AU - Brindle, K. M.

AU - Evelhoch, J. L.

AU - Griffiths, J. R.

AU - Horsman, M. R.

AU - Jackson, A.

AU - Jayson, G. C.

AU - Judson, I. R.

AU - Knopp, M. V.

AU - Maxwell, R. J.

AU - McIntyre, D.

AU - Padhani, A. R.

AU - Price, P.

AU - Rathbone, R.

AU - Rustin, G. J.

AU - Tofts, P. S.

AU - Tozer, G. M.

AU - Vennart, W.

AU - Waterton, J. C.

AU - Williams, S. R.

AU - Workman, P.

PY - 2005/5/9

Y1 - 2005/5/9

N2 - Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used. © 2005 Cancer Research UK.

AB - Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used. © 2005 Cancer Research UK.

KW - Antiangiogenic

KW - Antivascular

KW - Biomarker

KW - Cancer therapy

KW - Magnetic resonance

KW - Therapeutic trials

U2 - 10.1038/sj.bjc.6602550

DO - 10.1038/sj.bjc.6602550

M3 - Article

C2 - 15870830

SN - 0007-0920

VL - 92

SP - 1599

EP - 1610

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 9

ER -

The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this